A fleeting DNA fold called i‑DNA can switch cancer‑related genes on and off, revealing a hidden structural weak point that future therapies might exploit to collapse tumors.

Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage ...

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...

Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...

Readouts of the full DNA of children with cancer at diagnosis have been implemented as the standard of care in a European first. By determining a child's type of cancer as precisely as possible, the ...

ctDNA MRD monitoring may augment scans and tumor markers, enabling earlier detection of gastroesophageal cancer recurrence, especially hard-to-image peritoneal relapse.

A study published today in the journal Science reveals how jumping fragments of human DNA, a type of genetic parasite, ...

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

Serum tumor markers (STMs), including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are currently used in management of patients with germ cell tumors (GCTs). STMs in a substantial ...

Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364). Invasive ...